Sander van Deventer

Sander van Deventer

Naarden, Noord-Holland, Nederland
5K volgers Meer dan 500 connecties

Lid worden en volgen

Info

I had a critical role in the development of the first commercial monoclonal antibody (Remicade) the first commercial gene therapy in the Western world (Glybera) and multiple gene therapies reaching the clinic clinic for acute intermittent porphyria, lysosomal storage diseases and neurodegenerative diseases. I led the development of Hemgenix (AAV5-FIX) for which the FDA accepted the Biologics License Application for priority review in May 2022, as well as the Huntington silencing program at uniQure. I was one of the founding partners, former Managing Partner and current Operating Partner at Forbion Capital Partners, a venture capital firm investing in the life sciences in Europe and North America. I have more than 20 years experience at boards of private, Euronext- and Nasdaq-listed companies, chairing audit, compensation, nomination and governance committees, and have served as CEO of a Euronext-listed company.

I was trained as an internist and board-certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 I co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure; NASDAQ: QURE ), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, I chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. I have authored more than 80 book chapters, 600 peer review scientific papers, have organized several large international scientific conferences, and supervised more than 40 PhD students. Bibliographic summary (Google Scholar April 2024: Citations 72210; H-Index: 130).
In 2020 I co-founded VectorY Therapeutics, a gene therapy company based in Amsterdam that develops novel AAV vectors delivering molecular binders (VecTabs) and protein degraders (VecTrons) that allow precision targeting of the protein misfolding and aggregation which is central to the pathogenesis of neurodegenerative diseases. VectorY reported preclinical therapeutic activity of VecTabs and VecTrons at several international scientific meetings.

I like to cycle (road, gravel, MTB) and I am co-owner of two bicycle shops in the Netherlands.

Artikelen van Sander

Activiteit

Neem nu deel om alle activiteiten te bekijken

Ervaring

  • VectorY grafisch

    VectorY

    Amsterdam, Netherlands

  • -

    Naarden, The Netherlands

  • -

    Haarlem, the Netherlands

  • -

    Amsterdam, North Holland, Netherlands

  • -

    Suzhou, Jiangsu, China

  • -

  • -

    Amsterdam Area, Netherlands

  • -

    Amsterdam

  • -

  • -

    Naarden, The Netherlands

  • -

  • -

  • -

  • -

  • -

Opleiding

  • grafisch

    -

    Activiteiten en verenigingen:Professor and Chairman Experimental Medicine Professor and Chairman Gastroenterolofy and Hepatology

  • -

Ervaring als vrijwilliger

  • TuBerculosis Vaccine Initiative (TBVI) grafisch

    Board Member

    TuBerculosis Vaccine Initiative (TBVI)

    - heden 9 jaar 5 maanden

    Gezondheid

    The TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people. As a Product Development Partnership (PDP), TBVI integrates, translates and prioritises R&D efforts to discover and develop new TB vaccines and biomarkers for global use.

Patenten

  • Alanine-glyoxylate aminotransferase therapeutics

    Toegekend EU EP 2384200 A1

  • Porphobilinogen Deaminase Therapy

    Toegekend US US 2011/0262399 A1

  • Hedgehog-related prophylaxis, therapy and diagnosis of GI carcinogenesis

    Toegekend US US 2006/0058227 A1

  • Treatment of non-alcoholic steatotic hepatitis

    Toegekend US US 2008/0280823 A1

  • Synthetic peptides with antimicrobial and endotoxin-neutralizing properties for the treatment of the sepsis syndrome

    Toegekend US US 6624140

  • IL-10 gene transfer to mononuclear cells

    Toegekend US US 811940

  • Human therapeutic uses of BPI protein products

    Toegekend EU EP1161952 A3

  • GENE CONSTRUCTS FOR SILENCING ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND USES THEREOF

    Ingediend op 20230265434

  • Adeno-associated virus vectors for expressing fviii mimetics and uses thereof

    NL WO2020104480A1

  • Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis

    US US20060058227A1

  • Method and means to deliver mirna to target cells

    NL WO2020104469A1

  • Targeting mis-spliced transcript in genetic disorders

    US 2022/0213482

  • Use of il-18 inhibitors

    US US20030157094A1

  • methods and means to deliver miRNAto target cells

    US0371862

Talen

  • English

    Volledige professionele vaardigheid

  • German

    Professionele werkvaardigheid

  • French

    Beperkte werkvaardigheid

Meer activiteiten van Sander

Bekijk het volledige profiel van Sander

  • Bekijk wie u allebei kent
  • Word voorgesteld
  • Neem rechtstreeks contact op met Sander
Word lid en bekijk het volledige profiel

Overige vergelijkbare profielen

Anderen hebben Sander van Deventer genoemd

2 anderen door wie Sander van Deventer is genoemd, gebruiken LinkedIn

Bekijk anderen die Sander van Deventer heten

Voeg nieuwe vaardigheden toe met behulp van deze cursussen

Alle cursussen weergeven